Aktuellt
SENASTE
Redeye’s first take on the Q3 report this morning. There were considerable changes in sales in the different regions during the quarter. Cellavision presented a report that was slightly weaker on the top line but also had higher costs, primarily R&D, than we expected. The outcome of the regions fluctuated a lot in the quarter, with a strong development in EMEA, while both APAC and the Americas were relatively weak. We will adjust our estimates negatively; also, the volatility in sales development in different geographical areas increases uncertainty. We do not expect to change our Base case of SEK 250 per share significantly.
LÄS MER
